RU2000127105A - COMPOUNDS WITH ACTIVITY WITH RESPECT TO MUSCARINE RECEPTORS - Google Patents
COMPOUNDS WITH ACTIVITY WITH RESPECT TO MUSCARINE RECEPTORSInfo
- Publication number
- RU2000127105A RU2000127105A RU2000127105/04A RU2000127105A RU2000127105A RU 2000127105 A RU2000127105 A RU 2000127105A RU 2000127105/04 A RU2000127105/04 A RU 2000127105/04A RU 2000127105 A RU2000127105 A RU 2000127105A RU 2000127105 A RU2000127105 A RU 2000127105A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound according
- compound
- alkoxy
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000005842 heteroatoms Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrugs Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- -1 amino, hydroxyl Chemical group 0.000 claims 3
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Claims (1)
где X1, Х2, Х3, Х4 и X5 выбираются из CH2, NH и О;
k равно 0 или 1;
R1 является нормальным или разветвленным C1-8 алкилом, C2-8 алкенилом, C2-8 алкинилом, C1-8 алкилиденом, C1-8 алкокси, C1-8 гетероалкилом, C1-8 аминоалкилом, C1-8 галогеналкилом, C1-8 алкоксикарбонилом, C1-8 гидроксиалкокси, C1-8 гидроксиалкилом, -SH, C1-8 алкилтио, -O-CH2-C5-6 арилом, -С(О)-C5-6 арилом, замещенным C1-3 алкилом или галогеном; C5-6 арилом или C5-6 циклоалкилом, необязательно включающими 1 или более гетероатомов, выбранных из N, S и O; -C(O)NR3R4, -NR3R4, -NR3C(O)NR4R5, -СR3R4, -ОС(O)R3, -(O) (CH2)sNR3R4 или - (CH2)sNR3R4, где R3, R4 и R5 являются одинаковыми или разными, каждый независимо выбирается из H, C1-6 алкила; C5-6 арила, необязательно включающего 1 или более гетероатомов, выбранных из N, О и S, и необязательно замещенного галогеном или C1-6 алкилом; С3-6 циклоалкила, или R3 и R4 вместе с атомом N, когда они присутствуют, образуют циклическую кольцевую структуру, включающую 5-6 атомов, выбранных из С, N, S и О; и s равно целому числу от 0 до 8,
t равно 0, 1 или 2, радикалы R1, когда t равно 2, являются одинаковыми или разными;
А является C5-12 арилом или C5-7 циклоалкилом, каждый необязательно включающий 1 или более гетероатомов, выбранных из N, S и О;
R2 является Н, амино, гидроксилом, галогеном или нормальным или разветвленным C1-6 алкилом, C2-6 алкенилом, С2-6 алкинилом, C1-6 алкокси, C1-6 гетероалкилом, C1-6 аминоалкилом, C1-6 галогеналкилом, C1-6 алкоксикарбонилом, C1-6 алкилтио, -CN, -СF3, -ОR3, -COR3, NO2, -NHR3, -NHC(O)R3, -C(O)NR3R4, -NR3R4, -NR3C(O)NR4R5, -ОС(O)R3, -С(O)R3Р4, -O(CH2)qNR3, -СNR3R4 или - (CH2)qNR3R4, где q равно целому числу от 1 до 6;
n равно 0, 1, 2, 3 или 4, радикалы R2, где n > 1, являются одинаковыми или разными;
р равно 0 или целому числу от 1 до 5;
y является О, S, CHOH, -NHC(O)-, -C(O)NH-, -С(О)-, -ОС (О)-, NR7 или -СН= N-, и R7 является Н или C1-4 алкилом; или отсутствует;
Z является СR8R9, где R8 и R9 независимо выбираются из H и нормального или разветвленного C1-8 алкила,
его фармацевтически приемлемая соль, эфир или пролекарство.1. The compound of formula I
where X 1 , X 2 , X 3 , X 4 and X 5 are selected from CH 2 , NH and O;
k is 0 or 1;
R 1 is normal or branched C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, C 1-8 heteroalkyl, C 1-8 aminoalkyl, C 1 -8 haloalkyl, C 1-8 alkoxycarbonyl, C 1-8 hydroxyalkoxy, C 1-8 hydroxyalkyl, -SH, C 1-8 alkylthio, -O-CH 2 -C 5-6 aryl, -C (O) -C 5-6 aryl, substituted C 1-3 alkyl or halogen; C 5-6 aryl or C 5-6 cycloalkyl, optionally including 1 or more heteroatoms selected from N, S and O; -C (O) NR 3 R 4 , -NR 3 R 4 , -NR 3 C (O) NR 4 R 5 , -CR 3 R 4 , -OC (O) R 3 , - (O) (CH 2 ) s NR 3 R 4 or - (CH 2 ) s NR 3 R 4 , where R 3 , R 4 and R 5 are the same or different, each independently selected from H, C 1-6 alkyl; C 5-6 aryl, optionally including 1 or more heteroatoms selected from N, O and S, and optionally substituted with halogen or C 1-6 alkyl; C 3-6 cycloalkyl, or R 3 and R 4 together with the N atom, when they are present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 0 to 8,
t is 0, 1 or 2, the radicals R 1 , when t is 2, are the same or different;
A is C 5-12 aryl or C 5-7 cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O;
R 2 is H, amino, hydroxyl, halogen or normal or branched C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 heteroalkyl, C 1-6 aminoalkyl, C 1-6 haloalkyl, C 1-6 alkoxycarbonyl, C 1-6 alkylthio, —CN, —CF 3 , —OR 3 , —COR 3 , NO 2 , —NHR 3 , —NHC (O) R 3 , —C (O) NR 3 R 4 , -NR 3 R 4 , -NR 3 C (O) NR 4 R 5 , -OC (O) R 3 , -C (O) R 3 P 4 , -O (CH 2 ) q NR 3 , —CNR 3 R 4 or - (CH 2 ) q NR 3 R 4 , where q is an integer from 1 to 6;
n is 0, 1, 2, 3, or 4, the radicals R 2 , where n> 1, are the same or different;
p is 0 or an integer from 1 to 5;
y is O, S, CHOH, -NHC (O) -, -C (O) NH-, -C (O) -, -OC (O) -, NR 7 or -CH = N-, and R 7 is H or C 1-4 alkyl; or absent;
Z is CR 8 R 9 , where R 8 and R 9 are independently selected from H and normal or branched C 1-8 alkyl,
its pharmaceutically acceptable salt, ester or prodrug.
его фармацевтически приемлемая соль, эфир или пролекарство.2. The compound according to claim 1, wherein X 1 , X 2 , X 3 , X 4 and X 5 are CH 2 ; or one of X 1 , X 2 , X 3 , X 4 or X 5 is O or NH, and the others are CH 2 , k is 0 or 1, t is 1, R 1 is normal or branched C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkylidene, C 1-8 alkoxy, C 1-8 aminoalkyl, C 1-8 haloalkyl, C 1-8 alkoxycarbonyl, -C (O) NR 3 R 4 , -NR 3 R 4 , -NR 3 C (O) NR 4 R 5 , -OC (O) R 3 or - (CH 2 ) s NR 3 R 4 , where R 3 , R 4 and R 5 are the same or different, each independently selected from H and C 1-6 alkyl; and s is an integer from 1 to 8, n is 1, 2 or 3, and A is phenyl or naphthyl, where R 2 is normal or branched C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 aminoalkyl, C 1-6 haloalkyl, C 1-6 alkoxycarbonyl, —CN, —CF 3 , —OH, —OR 3 , —NHR 3 , —NHC (O) R 3 , -C (O) NR 3 R 4 , -NR 3 R 4 , -HR 3 C (O) NR 4 R 5 , -OC (O) R 3 or - (CH 2 ) q NR 3 R 4 , where q is an integer from 1 to 6; or A is aryl comprising 1 or more heteroatoms selected from N, S or O; R 2 is H, halogen, normal or branched C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 heteroalkyl, C 1-6 aminoalkyl, C 1 -6 halogenoalkyl, C 1-6 alkoxy-carbonyl, -CN, -CF 3 , -OH, -CO 3 , -NHR 3 , -NHC (O) R 3 , -C (O) NR 3 R 4 , -NR 3 R 4 , -NR 3 C (O) NR 4 R 5 , -OC (O) R 3 or - (CH 2 ) q NR 3 R 4 , or
its pharmaceutically acceptable salt, ester or prodrug.
6. Соединение по п. 5, представляющее собой соединение формулы IIа
7. Соединение по п. 5, представляющее собой соединение формулы IIb
8. Соединение по одному из пп. 5-7, где Х3 равняется CH2.5. Connection in one of the paragraphs. 1-3, which is a compound of formula II
6. The compound according to claim 5, which is a compound of formula IIa
7. The compound according to claim 5, which is a compound of formula IIb
8. Connection in one of the paragraphs. 5-7, where X 3 is equal to CH 2 .
где R1 является нормальным или разветвленным C1-8 алкилом, С2-8 алкенилом, C1-8 алкинилом, C1-8 алкилиденом, C1-8 алкокси, C1-8 гетероалкилом, C1-8 аминоалкилом, C1-8 галогеналкилом, C1-8 алкоксикарбонилом, C1-8 гидроксиалкокси, C1-8 гидроксиалкилом, -SH, C1-8 алкилтио, -О-СН2-С5-6 арилом, замешенным С1-3 алкилом или галогеном; C5-6 арилом или C5-6 ииклоалкилом, необязательно включающими 1 или более гетероатомов, выбранных из N, S и О; -С(O)NR3R4, -NR3R4, -ОС(O)R3, - (О) (CH2)sNR3R4 или - (СН2)sNR3R4, где R3, R4 и R5 являются одинаковыми или разными, каждый независимо выбирается из Н, C1-6 алкила; C5-6 арила, необязательно включающего 1 или более гетероатомов, выбранных из N, О и S, и необязательно замещенного галогеном или C1-6 алкилом; С3-6 циклоалкила или R3 и R4 вместе с атомом N, когда они присутствуют, образуют циклическую кольцевую структуру, включающую 5-6 атомов, выбранных из С, N, S и O; и s равно целому числу от 2 до 8, t равно 1 или 2, радикалы R1, когда t равно 2, являются одинаковыми или разными, А является C5-12 арилом или C5-7 циклоалкилом, каждый необязательно включающий 1 или более гетероатомов, выбранных из N, S и О, R2 является Н, амино, гидроксилом, галогеном или нормальным или разветвленным C1-6 алкилом, С2-6 алкенилом, С2-6 алкинилом, C1-6 алкокси, C1-6 гетероалкилом, C1-6 аминоалкилом, C1-6 галогеналкилом, C1-6 алкоксикарбонилом, C1-6 алкилтио, -CN, -СF3, -ОR3, -СОR3, NO2, -NHR3, -NНС(O)R3, -C(O)NR3R4, -NR3R4, -NR3C(O)NR4R5, -ОС(O)R3 или -С(O)R3R4, -O(CH2)qNR3, -СНR3R4 или - (CH2)qNR3R4, где q равно целому числу от 1 до 6, n равно 0, 1, 2, 3 или 4, радикалы R2, когда n > 1, являются одинаковыми или разными, р равно 0 или целому числу от 1 до 5, Y является O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -ОС(O)-, NR7 или -CK= N-, и R7 является Н или C1-4 алкилом; или отсутствует, Z является СR8R9, где R8 и R9 независимо выбираются из Н и нормального или разветвленного C1-8 алкила, при условии, что (a) когда t равно 1, R1 не является метилом, (b) когда t равно 2, R1 не является -C(O)NR3R4, (c) когда -Z-(CH2)p-Y- является - (СH2)3-С(О) - или -(СН2)3-S-, -A-(R2)n и R1 не являются вместе (i) о-метилом-фенилом и н-бутилом, соответственно, (ii) фенилом или н-бутилом, соответственно, и (iii) п-фтор-фенилом и -О-(СН2)2СН3, соответственно, или
его фармацевтически приемлемая соль, эфир или пролекарство.27. The compound according to claim 1, which has the General formula IA
where R 1 is normal or branched C 1-8 alkyl, C 2-8 alkenyl, C 1-8 quinil, C 1-8 alkylidene, C 1-8 alkoxy, C 1-8 heteroalkyl, C 1-8 aminoalkyl, C 1-8 halogenated, C 1-8 alkoxycarbonyl, C 1-8 hydroxyalkoxy, C 1-8 hydroxyalkyl, -SH, C 1-8 alkylthio, -O-CH 2 -C 5-6 aryl, substituted with C 1-3 alkyl or halogen; C 5-6 aryl or C 5-6 with cycloalkyl, optionally including 1 or more heteroatoms selected from N, S and O; -C (O) NR3R 4 , -NR 3 R 4 , -OC (O) R 3 , - (O) (CH 2 ) s NR 3 R 4 or - (CH 2 ) s NR 3 R 4 , where R 3 R 4 and R 5 are the same or different, each independently selected from H, C 1-6 alkyl; C 5-6 aryl, optionally including 1 or more heteroatoms selected from N, O and S, and optionally substituted with halogen or C 1-6 alkyl; C 3-6 cycloalkyl or R 3 and R 4 together with the N atom, when they are present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 2 to 8, t is 1 or 2, the radicals R 1 , when t is 2, are the same or different, A is C 5-12 aryl or C 5-7 cycloalkyl, each optionally including 1 or more heteroatoms selected from N, S and O, R 2 is H, amino, hydroxyl, halogen or normal or branched C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1 -6 heteroalkyl, C 1-6 aminoalkyl, C 1-6 haloalkyl, C 1-6 alkoxycarbonyl, C 1-6 alkylthio, —CN, —CF 3 , —OR 3 , —OR 3 , NO 2 , —NHR 3 , —NHC (O) R 3 , —C (O) NR 3 R 4 , —NR 3 R 4 , —NR 3 C (O) NR 4 R 5 , —OC (O) R 3 or —C (O) R 3 R 4 , -O (CH 2 ) q NR 3 , -CHR 3 R 4 or - (CH 2 ) q NR 3 R 4 , where q is an integer from 1 to 6, n is 0, 1, 2, 3 or 4, the radicals R 2 , when n> 1, are the same or different, p is 0 or an integer from 1 to 5, Y is O, S, CHOH, -NHC (O) -, -C (O) NH-, -C (O) -, -OC (O) -, NR 7 or —CK = N—, and R 7 is H or C 1-4 alkyl; or absent, Z is CR 8 R 9 , where R 8 and R 9 are independently selected from H and normal or branched C 1-8 alkyl, provided that (a) when t is 1, R 1 is not methyl, (b ) when t is 2, R 1 is not -C (O) NR 3 R 4 , (c) when -Z- (CH 2 ) p -Y- is - (СH 2 ) 3 -C (O) - or - (CH 2 ) 3 -S-, -A- (R 2 ) n and R 1 are not together (i) o-methyl-phenyl and n-butyl, respectively, (ii) phenyl or n-butyl, respectively, and (iii) p-fluoro-phenyl and -O- (CH 2 ) 2 CH 3 , respectively, or
its pharmaceutically acceptable salt, ester or prodrug.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8013398P | 1998-03-31 | 1998-03-31 | |
US60/080,133 | 1998-03-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004107218/04A Division RU2278111C2 (en) | 1998-03-31 | 2004-03-11 | Derivatives of nitrogen-containing heterocyclic compounds and medicinal agents based on thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000127105A true RU2000127105A (en) | 2002-08-27 |
RU2230740C2 RU2230740C2 (en) | 2004-06-20 |
Family
ID=22155464
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000127105/04A RU2230740C2 (en) | 1998-03-31 | 1999-03-31 | Derivatives of nitrogen-containing heterocyclic compounds and pharmaceutical composition based on thereof |
RU2004107218/04A RU2278111C2 (en) | 1998-03-31 | 2004-03-11 | Derivatives of nitrogen-containing heterocyclic compounds and medicinal agents based on thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004107218/04A RU2278111C2 (en) | 1998-03-31 | 2004-03-11 | Derivatives of nitrogen-containing heterocyclic compounds and medicinal agents based on thereof |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1068185A1 (en) |
JP (1) | JP2002509918A (en) |
KR (2) | KR20060120715A (en) |
CN (1) | CN1303376A (en) |
AR (1) | AR014974A1 (en) |
AU (1) | AU762726B2 (en) |
BR (1) | BR9909277A (en) |
CA (1) | CA2326804C (en) |
MX (1) | MXPA00009569A (en) |
NO (1) | NO319835B1 (en) |
NZ (2) | NZ507204A (en) |
RU (2) | RU2230740C2 (en) |
WO (1) | WO1999050247A1 (en) |
ZA (1) | ZA200005149B (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
ES2251624T3 (en) | 2001-12-28 | 2006-05-01 | Acadia Pharmaceuticals Inc. | ANALOGS OF TETRAHYDROQUINOLINE AS MUSCARINIC AGONISTS. |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
MXPA03000145A (en) | 2002-01-07 | 2003-07-15 | Pfizer | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators. |
GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
CA2499494A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
DOP2003000703A (en) | 2002-09-20 | 2004-03-31 | Pfizer | IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS |
HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
WO2005016276A2 (en) * | 2003-08-05 | 2005-02-24 | Samaritan Pharmaceuticals Inc. | Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
GEP20084550B (en) | 2004-04-30 | 2008-11-25 | Warner Lambert Co | Substituted morpholine compounds for the treatment of central nervous system disorders |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
MXPA06014486A (en) | 2004-06-15 | 2007-03-01 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
ME02222B (en) | 2004-12-30 | 2016-02-20 | Janssen Pharmaceutica Nv | Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
EP1939189A4 (en) | 2005-08-26 | 2013-03-13 | Shionogi & Co | Derivative having ppar agonistic activity |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
TWI385169B (en) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | Heterocyclic substituted pyridine derivatives and antifungal agent containing same |
EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
CL2008000119A1 (en) | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
AP2975A (en) | 2008-07-16 | 2014-09-30 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands |
HU230067B1 (en) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Novel piperazine salt and preparation method thereof |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
UA108233C2 (en) | 2010-05-03 | 2015-04-10 | Fatty acid amide hydrolysis activity modulators | |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
CN102558026A (en) * | 2011-12-27 | 2012-07-11 | 盛世泰科生物医药技术(苏州)有限公司 | Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1) |
US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
CN102997438A (en) * | 2012-10-16 | 2013-03-27 | 李誊 | Control method of electric water heater for improving heat utilization ratio |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
CN105073728A (en) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
CN105829310B (en) | 2013-12-20 | 2019-04-12 | 阿斯特克斯治疗有限公司 | Bicyclic heterocycles and its therapeutical uses |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
CN111093662B (en) | 2017-06-20 | 2023-10-03 | 安布里亚制药公司 | Compositions and methods for improving cardiac metabolic efficiency |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2695295A (en) * | 1952-12-19 | 1954-11-23 | Mcneilab Inc | Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds |
GB874206A (en) * | 1956-09-05 | 1961-08-02 | Knoll Ag | Basic derivatives of salicylamide |
NL271658A (en) * | 1960-12-01 | |||
FR1382425A (en) * | 1963-01-14 | 1964-12-18 | Ciba Geigy | Process for preparing diaza-cyclo-alkanes, inter alia 3-methyl-4-phenyl-1- (2-phenylmercapto-ethyl) -piperazine |
GB1053301A (en) * | 1963-01-14 | |||
US3488352A (en) * | 1966-10-11 | 1970-01-06 | Shulton Inc | Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof |
FR1543944A (en) * | 1967-03-10 | 1968-10-31 | Bruneau & Cie Lab | Salicylic acid amide derivatives and their preparation |
BE792187A (en) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | NEW ALKYLAMINE DERIVATIVES |
DE2335432A1 (en) * | 1973-07-12 | 1975-01-30 | Boehringer Mannheim Gmbh | 3,4-DIHYDRO-2H-NAPHTHALINONE- (1) 5-OXY-PROPYL-PIPERAZINE DERIVATIVES AND THE METHOD FOR THEIR PRODUCTION |
GB1459506A (en) * | 1974-02-18 | 1976-12-22 | Wyeth John & Brother Ltd | Piperidine derivatives |
GB1498884A (en) * | 1975-04-15 | 1978-01-25 | Wyeth John & Brother Ltd | Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
JP3390179B2 (en) * | 1996-08-15 | 2003-03-24 | シェーリング コーポレイション | Ether muscarinic antagonist |
-
1999
- 1999-03-31 RU RU2000127105/04A patent/RU2230740C2/en active
- 1999-03-31 BR BR9909277-8A patent/BR9909277A/en not_active Application Discontinuation
- 1999-03-31 KR KR1020067023572A patent/KR20060120715A/en not_active Application Discontinuation
- 1999-03-31 CN CN99806618A patent/CN1303376A/en active Pending
- 1999-03-31 NZ NZ507204A patent/NZ507204A/en unknown
- 1999-03-31 AU AU32187/99A patent/AU762726B2/en not_active Ceased
- 1999-03-31 MX MXPA00009569A patent/MXPA00009569A/en active IP Right Grant
- 1999-03-31 WO PCT/US1999/007057 patent/WO1999050247A1/en active IP Right Grant
- 1999-03-31 KR KR1020007010780A patent/KR100672186B1/en not_active IP Right Cessation
- 1999-03-31 JP JP2000541152A patent/JP2002509918A/en not_active Withdrawn
- 1999-03-31 NZ NZ525108A patent/NZ525108A/en unknown
- 1999-03-31 EP EP99914306A patent/EP1068185A1/en not_active Withdrawn
- 1999-03-31 CA CA002326804A patent/CA2326804C/en not_active Expired - Fee Related
- 1999-04-05 AR ARP990101516A patent/AR014974A1/en not_active Application Discontinuation
-
2000
- 2000-09-26 ZA ZA200005149A patent/ZA200005149B/en unknown
- 2000-09-29 NO NO20004912A patent/NO319835B1/en unknown
-
2004
- 2004-03-11 RU RU2004107218/04A patent/RU2278111C2/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000127105A (en) | COMPOUNDS WITH ACTIVITY WITH RESPECT TO MUSCARINE RECEPTORS | |
RU2495873C2 (en) | New uracil compound or salt thereof possessing human deoxyuridine triphosphatase | |
RU2002101723A (en) | INDANYL SUBSTITUTED BENZENE CARBONAMIDES, METHOD FOR PRODUCING THEM, THEIR USE AS A MEDICINAL PRODUCT, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
KR950003294A (en) | Tricyclic benzazine vazopressin antagonist | |
EA200100766A1 (en) | QUINOLIN-2-ON-SUBSTITUTED HETEROAARYNE DERIVATIVES USED AS ANTI-TUMOR AGENTS | |
RU98110565A (en) | NEW COMPOUNDS AND THEIR COMPOSITIONS Possessing ANTI-INFLAMMATORY AND ANTI-THROMBOTIC ACTIVITY | |
HRP20010468B1 (en) | Azabicycloalkanes as ccr5 modulators | |
TR200003061T2 (en) | Quinoline derivatives | |
BRPI0513777A (en) | compound or a salt thereof, pharmaceutical composition, and use of a compound or salt thereof | |
RU2003120080A (en) | ORTHO-SUBSTITUTED NITROGEN-CONTAINING BISARYL COMPOUNDS FOR APPLICATION AS POTASSIUM CHANNEL INHIBITORS, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
KR970706270A (en) | Benzopyran and benzo-condensed compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists (BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4 (LTB4) ANTAGONISTS) | |
DK0791006T3 (en) | Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation | |
EA200100983A1 (en) | DERIVATIVES 13-METHYLERITROMYCIN | |
EA200200774A1 (en) | NEW CONNECTIONS, HAVING HYPOLIPIDEMIC, HYPOCHOLESTERYNAMIC ACTIVITY, METHOD OF THEIR PREPARATION AND CONTAINING THEIR COMPOSITION | |
IT1230859B (en) | 2 ALCHYLYLPHENOLS SUBSTITUTED FOR ANTI-INFLAMMATORY ACTION, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
RU2004130487A (en) | ASETHIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | |
RU2004126700A (en) | Synthesis of Ecteinascidins Encountered in Nature and Related Compounds | |
DK0791005T3 (en) | Inhibitors of smooth muscle cell proliferation | |
RU2005119172A (en) | 4-ANILINKHINAZOLINE DERIVATIVES FOR TREATMENT OF PATHOLOGICAL CELL GROWTH | |
BRPI0415109A (en) | 1- [2- (4-hydroxyphenyl) -2-hydroxyethyl] -piperidin-4-ol compounds as nmda receptor antagonists | |
ES2064057T3 (en) | SOME DERIVATIVES OF 2- (AMINOALKYL) -5- (ARILALKYL) -1,3-DIOXANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS. | |
YU52498A (en) | USE OF 2-ARYLBENZEN (b) THIOPHENE FOR MEDICAMENT PREPARATION | |
SE7706976L (en) | PROCEDURE FOR THE PREPARATION OF INDOLETIC ACID ESTERAL DERIVATIVES | |
RU2003114754A (en) | METHOD FOR PRODUCING BISBENZAZOZYL COMPOUNDS | |
RU96101173A (en) | PYRIDASINON DERIVATIVES |